StockNews.AI
GILD
StockNews.AI
79 days

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

1. Kite presents real-world data on Yescarta® for outpatient vs inpatient treatment. 2. Findings may influence treatment choices for relapsed/refractory lymphoma patients.

2m saved
Insight
Article

FAQ

Why Bullish?

The positive outcomes of Yescarta® could enhance Gilead's competitive position and sales. Previous announcements of successful trials have often led to price increases for similar biopharmaceutical companies.

How important is it?

The real-world data on Yescarta®'s effectiveness represents significant clinical evidence that could lead to increased market confidence and patient adoption.

Why Short Term?

The results present immediate implications for treatment protocols, potentially impacting demand rapidly as healthcare providers adapt to new findings.

Related Companies

BMYJNJAMGN
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta® (axicabtagene ciloleucel) for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) assigned to treatment in an outpatient setting (no planned hospital stay) versus those assigned to an inpatient setting in a hospital. The analysis, based on data collected from the Center for International Blood and Marrow Transplant Rese.

Related News